Nonclinical safety evaluation of pabinafusp alfa, an anti-human transferrin receptor antibody and iduronate-2-sulfatase fusion protein, for the treatment of neuronopathic mucopolysaccharidosis type II

MLA

Ryuji Yamamoto, et al. “Nonclinical Safety Evaluation of Pabinafusp Alfa, an Anti-Human Transferrin Receptor Antibody and Iduronate-2-Sulfatase Fusion Protein, for the Treatment of Neuronopathic Mucopolysaccharidosis Type II.” Molecular Genetics and Metabolism Reports, vol. 27, no. 100758-, June 2021. EBSCOhost, https://doi.org/10.1016/j.ymgmr.2021.100758.

APA

Ryuji Yamamoto, Eiji Yoden, Noboru Tanaka, Masafumi Kinoshita, Atsushi Imakiire, Tohru Hirato, & Kohtaro Minami. (2021). Nonclinical safety evaluation of pabinafusp alfa, an anti-human transferrin receptor antibody and iduronate-2-sulfatase fusion protein, for the treatment of neuronopathic mucopolysaccharidosis type II. Molecular Genetics and Metabolism Reports, 27(100758-). https://doi.org/10.1016/j.ymgmr.2021.100758

Chicago

Ryuji Yamamoto, Eiji Yoden, Noboru Tanaka, Masafumi Kinoshita, Atsushi Imakiire, Tohru Hirato, and Kohtaro Minami. 2021. “Nonclinical Safety Evaluation of Pabinafusp Alfa, an Anti-Human Transferrin Receptor Antibody and Iduronate-2-Sulfatase Fusion Protein, for the Treatment of Neuronopathic Mucopolysaccharidosis Type II.” Molecular Genetics and Metabolism Reports 27 (100758-). doi:10.1016/j.ymgmr.2021.100758.